<DOC>
	<DOCNO>NCT00563953</DOCNO>
	<brief_summary>This multicenter study primary chemotherapy regimen breast cancer patient risk develop cardiotoxicity . The aim study evaluate response rate surgery .</brief_summary>
	<brief_title>Caelyx Primary Treatment Patients With Breast Cancer History Heart Disease and/or Age Over 65 Years</brief_title>
	<detailed_description>This phase II , uncontrolled , open label , multicenter study primary chemotherapy regimen consist four cycle liposomal pegylated doxorubicine 35 mg/m² IV plus cyclophosphamide 600 mg/m² Day 1 every 4 week follow paclitaxel 80 mg/m²/week 12 week surgery breast cancer patient risk develop anthracycline-induced cardiotoxicity . Surgery ( tumorectomy , quadrantectomy , mastectomy plus lymphadenectomy ) perform 2 5 week last primary chemotherapy infusion . Patients &gt; 10 % hormone receptor-positive cell receive appropriate hormone therapy accord menopausal status . Patients treat breast-conserving surgery receive radiation therapy mammary gland . Patients T4 tumor significant axillary involvement ( ≥ ypN2 ) receive radiation therapy breast chest wall lymph node chain .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histologically confirm invasive breast cancer ( tumor &gt; 2 cm ) . Estrogen receptornegative weakly positive tumor ( less 50 % cell ) , evaluate use IHC . Risk factor develop anthracyclineinduced cardiomyopathy . Severe heart failure ( NYHA Class III IV ) . Metastatic disease . LVEF &lt; 45 % . Pregnant breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>Anthracyclines</keyword>
	<keyword>Cardiopathy</keyword>
</DOC>